文献速递炎症性肠病

炎症性肠病患者生物制剂治疗序贯与第二种抗TNF药物选择的意义:IMSAT治疗药物监测研究结果

Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.
PubMed 文献 · Aliment Pharmacol Ther · 2022-08-29

英国多中心回顾性队列研究纳入1058例先后接受英夫利西单抗和阿达木单抗治疗药物监测的IBD患者,评估第一种抗TNF药物免疫原性与第二种免疫原性的关联。结果显示无论用药顺序,第一种抗TNF的免疫原性与第二种免疫原性相关,换药时启用免疫调节剂可改善免疫原性失败患者的药物持续使用。

要点

  • 第一种抗TNF免疫原性与第二种抗TNF免疫原性相关,不受用药顺序影响。
  • 英夫利西单抗后阿达木单抗:有抗英夫利西西单抗抗体者后续抗阿达木单抗抗体风险OR 1.99。
  • 阿达木单抗后英夫利西单抗:有抗阿达木单抗抗体者后续抗英夫利西单抗抗体风险OR 2.63。

核心结论

  • 无论药物顺序,对第一种抗TNF药物的免疫原性与对第二种的免疫原性相关,在免疫原性失败(而非药效学失败)患者中换药时加用免疫调节剂可减轻这种关联。

研究设计与样本

  • 英国全国多中心回顾性队列研究,纳入1058例接受英夫利西单抗和阿达木单抗治疗药物监测的炎症性肠病患者。

主要发现

  • 英夫利西单抗后换用阿达木单抗者中,对英夫利西单抗产生抗体者后续对阿达木单抗产生抗体的风险更高(OR 1.99,95%CI 1.27-3.20,p=0.002)。
  • 阿达木单抗后换用英夫利西单抗者中,对阿达木单抗免疫原性与后续对英夫利西单抗免疫原性相关(OR 2.63,95%CI 1.46-4.80,p<0.001)。
  • 抗英夫利西单抗抗体浓度每增加10倍,后续产生抗阿达木单抗抗体的比值增加1.73(95%CI 1.38-2.17,p<0.001)。
  • 抗阿达木单抗抗体浓度每增加10倍,后续产生抗英夫利西单抗抗体的比值增加1.99(95%CI 1.34-2.99,p<0.001)。
  • 对英夫利西单抗免疫原性且药物浓度检测不到者,后续对阿达木单抗免疫原性且药物浓度检测不到的风险更高(OR 2.37,95%CI 1.39-4.19,p<0.001)。

关键数值与推荐

  • 第二次抗TNF免疫原性定义为任一时刻抗TNF抗体浓度英夫利西单抗≥9 AU/ml、阿达木单抗≥6 AU/ml。

临床怎么用

  • 在免疫原性失败(而非药效学失败)患者中,换用第二种抗TNF时启用免疫调节剂与更好的药物持续使用相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-drug antibodies are associated with treatment failure to anti-TNF agents in patients with inflammatory bowel disease (IBD). AIM: To assess whether immunogenicity to a patient's first anti-TNF agent would be associated with immunogenicity to the second, irrespective of drug sequence METHODS: We conducted a UK-wide, multicentre, retrospective cohort study to report rates of immunogenicity and treatment failure of second anti-TNF therapies in 1058 patients with IBD who underwent therapeutic drug monitoring for both infliximab and adalimumab. The primary outcome was immunogenicity to the second anti-TNF agent, defined at any timepoint as an anti-TNF antibody concentration ≥9 AU/ml for infliximab and ≥6 AU/ml for adalimumab. RESULTS: In patients treated with infliximab and then adalimumab, those who developed antibodies to infliximab were more likely to develop antibodies to adalimumab, than patients who did not develop antibodies to infliximab (OR 1.99, 95%CI 1.27-3.20, p = 0.002). Similarly, in patients treated with adalimumab and then infliximab, immunogenicity to adalimumab was associated with subsequent immunogenicity to infliximab (OR 2.63, 95%CI 1.46-4.80, p < 0.001). For each 10-fold increase in anti-infliximab and anti-adalimumab antibody concentration, the odds of subsequently developing antibodies to adalimumab and infliximab increased by 1.73 (95% CI 1.38-2.17, p < 0.001) and 1.99 (95%CI 1.34-2.99, p < 0.001), respectively. Patients who developed immunogenicity with undetectable drug levels to infliximab were more likely to develop immunogenicity with undetectable drug levels to adalimumab (OR 2.37, 95% CI 1.39-4.19, p < 0.001). Commencing an immunomodulator at the time of switching to the second anti-TNF was associated with improved drug persistence in patients with immunogenic, but not pharmacodynamic failure. CONCLUSION: Irrespective of drug sequence, immunogenicity to the first anti-TNF agent was associated with immunogenicity to the second, which was mitigated by the introduction of an immunomodulator in patients with immunogenic, but not pharmacodynamic treatment failure.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chanchlani N, Lin S, Auth MK, et al. Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study. Aliment Pharmacol Ther. 2022. PMID: 36039036. doi:10.1111/apt.17170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。